Fig. 9
From: HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinoma
The HSF1 inhibitor KRIBB11 reduces the glycolytic metabolism of cholangiocarcinoma cell lines. A Glycolytic rate profiles of human HuCCT1 and KKU-M156 cell lines treated with 10 µM KRIBB11 and matching DMSO concentration for 24 h. Seahorse XF Glycolytic Rate assays (Agilent) were performed employing serial injections of Rot/AA, and 2-DG and Hoechst 33342 for nuclei staining; the PER reflecting the glycolytic function was measured using the Seahorse XF HS mini analyzer. B Changes in basal glycolysis, compensatory glycolysis, and basal PER. Data were background corrected and normalized to cell number as determined by Hoechst 33342 nuclei staining; a factor of 105 was applied. Graphs depict the mean ± SEM of two independent experiments each performed in technical triplicates (multiple Mann–Whitney tests; *p < 0.05). Abbreviations: PER, proton efflux rate (in pmol/min); Rot/AA, rotenone/antimycin A; 2-DG, 2-deoxy-D-glucose